Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 47Cisplatin 24Cetuximab 23Paclitaxel 18Nivolumab 18Radiotherapy 15Docetaxel 15Carboplatin 14Fluorouracil 11tremelimumab 7durvalumab 7Erlotinib Hydrochloride 6avelumab 5Radiotherapy, Intensity-Modulated 5Radiosurgery 5Pemetrexed 4Ipilimumab 4Immunoglobulin G 4Gemcitabine 4Fulvestrant 4Capecitabine 4Bevacizumab 4epacadostat 3cemiplimab 3atezolizumab 3Taxes 3Radiation 3Everolimus 3Cyclophosphamide 3Amifostine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Squamous Cell Carcinoma of Head and Neck × NVP-BKM120 × Clear all
NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

University of Chicago

Phase 1/2 Completed
12 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡